CMT-DARS2

DARS2 | 2025

What Is CMT-DARS2?

CMT-DARS2 is a type of CMT caused by autosomal recessive mutations in the DARS2 gene. This gene provides instructions for making the mitochondrial aspartyl-tRNA synthetase, an enzyme required for building proteins inside mitochondria. Mutations in the DARS2 gene disrupt mitochondrial protein synthesis, leading to impaired nerve signal transmission.

CMT-DARS2 is autosomal recessive, meaning that both copies of the gene must have a mutation to cause this subtype.

Clinical Features

The age of symptom onset in CMT-DARS2 is variable, ranging from childhood to adulthood. Symptoms typically begin in the lower extremities and progress over time to involve the upper limbs. Nerve conduction studies usually show somewhat slowed conduction velocities and reduced amplitudes, consistent with an axonal form of CMT.

CMT-DARS2 symptoms may include:

  • Weakness in the feet and lower legs
  • Muscle atrophy
  • Foot drop
  • Reduced or absent reflexes
  • Reduced sensation
  • A steppage-style walking pattern
  • Foot deformities, including high arches, and hammertoes (clawed toes)
  • Progressive involvement of the hands and forearms
  • Difficulty with fine motor skills and manual dexterity
  • Additional symptoms not listed here

Disease Course

CMT-DARS2 shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
CMT-DARS2

Classification
Unclassified Subtypes

Neuropathy Type
Axonal

Inheritance Pattern
autosomal recessive

Genetic Context

HGNC-Approved Gene Symbol
DARS2

Gene Full Name
Aspartyl-tRNA Synthetase 2, Mitochondrial

HGNC Gene Alias(es)
FLJ10514

Chromosome
1q25.1

Zygosity of Responsible Variant
Compound Heterozygous

Mitochondrial Involvement
Yes

Variant Mechanism
Loss of Function (LoF)

ClinVar Pathogenic Variants

View CMT-DARS2 ClinVar Variants

DARS2 OMIM Entry

DARS2 OMIM

More Info

CMT-DARS2 Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Biallelic Variants in the DARS2 Gene as a Novel Cause of Axonal Charcot-Marie-Tooth Disease

Authors

Estévez-Arias, B., Sarv, S., Bonello-Palot, N., Carrera-García, L., Ortez, C., Expósito-Escudero, J., Yubero, D., Muchart, J., Delmont, E., Õiglane-Shlik, E., Meren, T., Puusepp, S., Murumets, Ü., Salomons, G. S., Udd, B., Väli, L., Cantarero, L., Bönnemann, C. G., Nascimento, A., Ramón-Maiques, S., Õunap, K., Hoenicka, J., Natera-de Benito, D., Palau, F.

Publication Date
August 15, 2025

Updated: July 18, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.


Illustrated cover graphic showing a split landform with branching directional arrows, two people with question marks above their heads, and the title ‘SORD Deficiency: Decoding This Newly Discovered and Confusing CMT Subtype.


CMT-SORD: What Is This Unique CMT Subtype?

CMT-SORD is a newly discovered CMT subtype driven by toxic sorbitol accumulation. This article explains how "SORD" works, why this subtype is different, and how it led to the fastest-moving therapeutic program in CMT history.